Hims & Hers Health Inc

Hims & Hers Health Inc(HIMS)股票分析

$29.320

+1.469 (+5.01%)收盤時

Loading chart…
最高
29.805
開盤
27.710
成交量加權均價
28.91
成交量
12.28M
市值
4.30B
最低
27.600
成交金額
354.97M
企業價值/稅息折舊攤銷前利潤(TTM)
-17.45

Hims & Hers Health, Inc. operates as a consumer-first platform, which helps customers to fulfill their health and wellness needs. Its platform includes access to a provider network, a clinically focused electronic medical record system, digital prescriptions, cloud-enabled pharmacy fulfillment, and personalization capabilities. Its digital platform enables access to treatments for a range of conditions, including primarily those related to sexual health, hair loss, hormone health, weight loss, dermatology, and mental health, as well as services such as comprehensive laboratory testing. It connects patients to licensed healthcare professionals who can prescribe medications when appropriate and prescriptions are fulfilled online through licensed pharmacies. It also offers access to a range of health and wellness products designed to meet individual needs, which can include curated prescription and non-prescription products.

AI 分析 of Hims & Hers Health Inc (HIMS)

持有

Hims & Hers Health Inc is currently not a strong buy due to its recent performance and financial instability. The current price is $27.71, with a significant decline of 42.55% over the past year. Additionally, the RSI is at 36.78, indicating that the stock is nearing oversold territory but has not yet reversed its trend. The forward P/E ratio is high at 73.53, suggesting that the stock may be overvalued given its current earnings situation. The main risk is the ongoing class action lawsuit related to FTC allegations, which could further impact investor sentiment and stock performance.

估值指標

Hims & Hers Health Inc(HIMS)目前預期本益比為 71.94,5 年平均預期本益比為 18.69。

預期本益比

合理
5 年均值 P/E
18.69
目前P/E
71.94
高估
76.52
低估
-39.14

預期 EV/EBITDA

合理
5 年均值 EV/EBITDA
13.61
目前EV/EBITDA
-17.45
高估
46.29
低估
-19.08

預期股價營收比

合理
5 年均值 P/S
2.47
目前P/S
1.61
高估
3.52
低估
1.43

Alphio AI 對 HIMS 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%HIMS

$133.17

情境價格

基

基準

基準 · 50%HIMS

$111.56

情境價格

悲

悲觀

悲觀 · 25%HIMS

$85.01

情境價格

持有 HIMS 的大戶

T

The State of Michigan Retirement Systems

+ 持有HIMS

+5.22%

3個月報酬率

S

Summit Trail Advisors, LLC

+ 持有HIMS

+2.51%

3個月報酬率

C

Casdin Capital, LLC

+ 持有HIMS

-0.44%

3個月報酬率

B

BIT Capital GmbH

+ 持有HIMS

-3.28%

3個月報酬率

D

Divisadero Street Capital Management, LP

+ 持有HIMS

-8.80%

3個月報酬率

HIMS 常見問題 —— 由 Alphio AI 解答

Hims & Hers Health, Inc. operates as a consumer-first platform, which helps customers to fulfill their health and wellness needs. Its platform includes access to a provider network, a clinically focused electronic medical record system, digital prescriptions, cloud-enabled pharmacy fulfillment, and personalization capabilities. Its digital platform enables access to treatments for a range of conditions, including primarily those related to sexual health, hair loss, hormone health, weight loss, dermatology, and mental health, as well as services such as comprehensive laboratory testing. It connects patients to licensed healthcare professionals who can prescribe medications when appropriate and prescriptions are fulfilled online through licensed pharmacies. It also offers access to a range of health and wellness products designed to meet individual needs, which can include curated prescription and non-prescription products. It operates in the Healthcare sector (SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE industry).

Hims & Hers Health Inc is currently not a strong buy due to its recent performance and financial instability. The current price is $27.71, with a significant decline of 42.55% over the past year. Additionally, the RSI is at 36.78, indicating that the stock is nearing oversold territory but has not yet reversed its trend. The forward P/E ratio is high at 73.53, suggesting that the stock may be overvalued given its current earnings situation. The main risk is the ongoing class action lawsuit related to FTC allegations, which could further impact investor sentiment and stock performance.

jadeprism9718 小時前

$HIMS had a nice rally on peptides, though there is still a lot unknown about the upside potential. Peptides are really just a bonus for an already cheap stock.

展開

Someone once told me about the 20SMA/50EMA crossover, so I'm always watching for it. $HIMS is tight around this crossover and looks set for a big expansion from here.

展開
jade_estuary2026/10/16

HIMS stock ended a three-day decline on peptide hopes: the Trump administration is reviewing a plan that could open a $2.2B market. $HIMS

展開
dawn_badger2026/10/9

$HIMS The price is wasting time ... but it's running out of room. Imminent resolution. Weekly chart

展開
註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易